Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company ...

Gilead Sciences (NASDAQ:GILD) has demonstrated a strong performance this year, with its stock up 18% compared to the S&P 500’s modest 2% gain.

As Gilead Sciences gets underway with the key launch of its twice-yearly pre-exposure prophylaxis (PrEP) HIV med, the company ...

Shares of Gilead Sciences Inc. rallied 2.83% to $110.67 Friday, on what proved to be an all-around great trading session for ...

See the latest Gilead Sciences GILD stock price (NASDAQ: GILD), related news, valuation, dividends and more to help you make your investing decisions.

Gilead Sciences (NASDAQ: GILD) saw its stock jump nearly 10% yesterday after announcing groundbreaking results from its HIV treatment trial. The biopharmaceutical company revealed 100% efficacy in its ...

Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered ...

Gilead's CEO says he's committed to making sure people around the world can get his firm's new HIV prevention shot Yeztugo.

Gilead Sciences has entered into an option and license deal with Kymera Therapeutics to support the development and sales of ...

Gilead Sciences Inc. closed 11.48% below its 52-week high of $119.96, which the company reached on March 10th.

More than a decade ago, researchers at Gilead Sciences thought they had a breakthrough: a new version of the company’s key HIV medicine that was less toxic to kidneys and bones.

Gilead Sciences Inc. closed 11.70% below its 52-week high of $119.96, which the company achieved on March 10th.